Revisiting NICE’s approval of ‘breakthrough’ drugs palbociclib and ribociclib
Claims of cancer drugs’ survival benefits must be accurate. To avoid fashion and fads, we must carefully examine the clinical and economic implications of newly approved cancer drugs before we seat them on the ‘breakthrough’ throne.
In November 2017, the National Institute fo…